DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Mature Cataracts
Interventions
DRUG

DYME

2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution

DRUG

DYME

2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution

Trial Locations (22)

11514

Island Eye Surgicenter, Carle Place

18704

Eye Care Specialists, Kingston

19107

Wills Eye Surgery Center, Philadelphia

19145

Wills Surgery Center, Philadelphia

33176

Center for Excellence in Eye Care, Miami

33770

The Eye Institute of West Florida, Largo

43210

The Ohio State University Hospital, Columbus

46256

Eye Surgeons of Indiana, Indianapolis

53715

SMDV Surgery Center, Madison

63141

Ballas Surgery Center, St Louis

64133

Silverstein Eye Centers, Kansas City

65804

St. John's Clinic Eye Specialists, Springfield

72703

McDonald Eye Associates, Fayetteville

90301

Peace Laser Eye Center, Inglewood

95815

Capitol City Surgery Center, Sacramento

560020

Narayana Nethralaya, Bangalore

560052

Bhagwan Mahaveer Jain Hospital, Bangalore

560099

Narayana Nethralaya, Bangalore

08002

Wills Eye Surgery Center, Cherry Hill

07424

Brar-Parekh Eye Associates, Woodland Park

400 005

The Mehta International Eye Institute & Colaba Eye Hospital, Mumbai

400 007

Bombay City Eye Institute & Research Centre, Mumbai

All Listed Sponsors
lead

Aqumen Biopharmaceuticals, N.A.

INDUSTRY

NCT00596583 - DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery | Biotech Hunter | Biotech Hunter